Astrazeneca stock: buy or sell
Updated on:
Jan 16th, 2021
1
Astrazeneca stock brief
- Counting on Friday, it's been 3 consecutive sessions in green for Astrazeneca. Price closed on Friday at $51.34 after just changing a 0.10%.
- Berenberg Bank and Deutsche Bank Aktiengesellschaft posted strong bullish ratings for Astrazeneca on Friday, with an average target of $0.00
Should I buy Astrazeneca stock?
All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best
Is $AZN stock a buy?
In the current situation of Astrazeneca there is not any eligible buy setup. This doesn't mean $AZN will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems
Should I sell Astrazeneca stock?
"To sell or not to sell", if you are holding Astrazeneca stock?. Like when we have to buy shares, deciding when is appropiate to sell is not a whimsical decision, and we must follow our own trading style. When selling, as well as buying, our strategies are very easy to follow but are only valid for selling shares in your porfolio, not for shorting $AZN stock
As a golden rule, you should not hold an open trade that produces greater losses than those expected at the time of the buy. The moment to sell your stock must always be ruled by the stop-loss (automatic or manual)
Is it time to sell Astrazeneca stock?
Currently, Astrazeneca stock doesn't match any of our preferred sell setups, so if you hold Astrazeneca stock and your operation is in profit probably is not time to sell now
Astrazeneca ratings
In the last month, 3 analyst ratings were published for Astrazeneca. General sentiment is bullish, with 2 out of 3 posting positive forecasts
| Brokerage firm | Rating |
|---|---|
| Dec 30th, 2020 | |
| AlphaValue | Neutral |
| Jan 15th, 2021 | |
| Berenberg Bank | |
| Deutsche Bank Aktiengesellschaft | |
Astrazeneca stock analysis
SMAs overview
Supports and resistances
The current resistances are:
The current support levels are:
Bollinger bands
The price is moving very close to the upper Bollinger band, signaling some level of overbought in recent sessions. This is not a bearish indicator, as price can move in these levels for many days and weeks
Relative strength index
When the moves for so long below 70 and above 30, without indication of overvaluation and undervaluation, the indicator gets of little use, and we find ourselves in one of these cases.
Astrazeneca stock price history
Astrazeneca went public priced at an adjusted price1 of $1.88 on May 1993. Since then, AZN stock surged by 2,630.85%, with an average of 97.44% per year. An investment of $1,000USD on the IPO would have a value of $27,308.51 today.
1: Adjusted price after possible price splits or reverse-splits
Price target for Astrazeneca stock
Nobody knows how much a stock will be priced tomorrow. However, many stock price predictions are published every day by banks, financial institutions and independent analysts.
Along with buy or sell recommendations, brokerage institutions publish their price estimates based on the stock price action and the company fundamental data. Most of these predictions follow the release of new fundamental information by the company, and many times. If you are a small investor you don't have to invest based on these predictions.
We don't have any target price posted in the previous 4 weeks for Astrazeneca.
| Brokerage firm | Price target |
|---|---|
| Dec 30th, 2020 | |
| AlphaValue | Not available |
| Jan 15th, 2021 | |
| Berenberg Bank | Not available |
| Deutsche Bank Aktiengesellschaft | Not available |
Earnings and financials
Last November, Astrazeneca ($AZN) hosted the quarterly shareholders event and released the report. Astrazeneca beat market estimates and reported of $0.47, that is a 6.82% surprise versus the previous estimates of $0.44. Despite this, reported revenues of $6.6 billion were in line with analysts forecasts.
This compares to Earnings of $0.50 per share a year ago, so current EPS means a reduction of -6.00%. Looking at revenue, figures scarcely changed compared to $64.1B same quarter a year ago.Astrazeneca ($AZN) will host the earnings call mid next February.
Astrazeneca performance
| Company | 1m | 3m | 6m |
|---|---|---|---|
| Astrazeneca ($AZN) | -0.90% | -3.10% | -17.40% |
Please read:
The opinions expressed in this article are personal and not recommendations for you to buy or sell shares. The author of this report does not know the particular conditions of the reader, his or her financial statements or his or her own best interests at any given time. All users should speak with their financial advisor before buying or selling any securities Opinions are published for general educational reasons onlyAstrazeneca summary
| Friday, January 15th, 2021 | |
|---|---|
| Open | $51.29 |
| Close | $51.34 |
| Day range | $51.13 - $51.56 |
| Previous close | $51.29 |
| Session gain | 0.10% |
| Average true range | $1.07 |
| 50d mov avg | $52.61 |
| 100d mov avg | $53.33 |
| 200d mov avg | $53.14 |
| Earnings date | February 12th, 2021 |